Ivonescimab Receives Priority Review for BTC in China
A New Chapter for Biliary Tract Cancer Treatment In the world of cancer treatment, gaining a regulatory nod often feels like hitting a tough milestone. Well, Akeso, Inc. is now basking in one of those high notes. Their flagship drug, ivonescimab, has snatched up a Priority Review from China's National Medical Products Administration (NMPA) for first-line treatment of...
Continue Reading